gadopentetic acid dimeglumine salt: clinical use

Prescribing considerations

• Diagnostic use only and specifically formulated for intra-articular administration; do not administer intravenously.
• Assess previous contrast reactions, asthma and allergic disease, and ensure immediate hypersensitivity treatment is available.
• Use particular caution when joint infection is suspected.
• Not recommended for children in the selected product information.
• The selected eMC product is marked as discontinued.

Contraindications and cautions

• Hypersensitivity to gadopentetic acid dimeglumine salt or any excipient.
• Assess MRI suitability separately for implanted devices or metallic foreign bodies.

Monitoring

• Observe for hypersensitivity during administration and for at least 30 minutes afterwards.
• Monitor joint and injection-site symptoms; delayed hypersensitivity-type reactions can occur.

Clinical pharmacology

Gadopentetate dimeglumine is an ionic, linear gadolinium chelate that shortens proton relaxation times and principally enhances signal on T1-weighted imaging. Material absorbed from the joint enters extracellular fluid and is eliminated mainly through the kidneys.

Formulation and product differences

• The selected product is a clear aqueous, low-concentration solution supplied in a pre-filled syringe for direct joint injection.
• It contains meglumine, pentetic acid, sodium chloride and water for injections.
• Do not confuse it with intravenous Magnevist presentations, whose EU authorisations were suspended; the intra-articular formulation remained subject to updated product information.